234094-01-0

Basic information

• Product Name: [1-(2-Amino-ethylcarbamoyl)-2-hydroxy-ethyl]-carbamic acid tert-butyl ester
• Synonyms: [1-(2-Amino-ethylcarbamoyl)-2-hydroxy-ethyl]-carbamic acid tert-butyl ester;2-Amino-3-(2-amino-ethylamino)-propan-1-ol;tert-butyl(S)-(1-((2-aminoethyl)amino)-3-hydroxy-1-oxopropan-2-yl)carbamate
• CAS NO: 234094-01-0
• Molecular Formula: C₁₀H₂₁N₃O₄
• Molecular Weight: 247.29144
• Mol File: 234094-01-0.mol

Chemical Properties

• Boiling Point: 488.71°C at 760 mmHg
• Flash Point: 249.363°C
• Appearance: /
• Density: 1.159g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.496
• CAS DataBase Reference: [1-(2-Amino-ethylcarbamoyl)-2-hydroxy-ethyl]-carbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: [1-(2-Amino-ethylcarbamoyl)-2-hydroxy-ethyl]-carbamic acid tert-butyl ester(234094-01-0)
• EPA Substance Registry System: [1-(2-Amino-ethylcarbamoyl)-2-hydroxy-ethyl]-carbamic acid tert-butyl ester(234094-01-0)

Safety Data

• Hazardous Substances Data: 234094-01-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H21N3O4/c1-10(2,3)17-9(16)13-7(6-14)8(15)12-5-4-11/h7,14H,4-6,11H2,1-3H3,(H,12,15)(H,13,16)/t7-/m0/s1

Upstream product

• 2766-43-0 N-tert-butyloxycarbonyl-L-serine methyl ester 
• 107-15-3 ethylenediamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 5680-80-8 methyl (2S)-2-amino-3-hydroxypropanoate hydrochloride 

Downstream Products

• 193901-91-6 2,2’-((2-(((2R)-2-(bis(carboxymethyl)amino)-3-((((4,4-diphenylcyclohexyl)oxy)(hydroxy)phosphoryl)oxy)propyl)(carboxymethyl)amino)ethyl)azanediyl)diacetic acid 

Relevant articles and documents

A practical manufacturing synthesis of 1-(R)-hydroxymethyl-DTPA: An important intermediate in the synthesis of MRI contrast agents

An efficient synthesis of alcohol 2 is described from L-Serine (OMe) in four synthetic steps. The process uses readily available reagents and is suitable for manufacturing.

PROCESS FOR MANUFACTURE OF GADOFOSVESET TRISODIUM MONOHYDRATE

This application relates to a process for making a pharmaceutically acceptable formulation of gadofosveset trisodium monohydrate, wherein the process uses no more than one chromatographic purification for removal of impurities.